While the science of quality measurements is still in its infancy, Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said these metrics have allowed her and her team to open the door of communication among providers on how important quality truly is.
While the science of quality measurements is still in its infancy, Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said in a panel discussion with her peers that these metrics have allowed her and her team to open the door of communication among providers and educate one another on how important quality truly is.
From a health plan perceptive, Dr Malin explained that quality metrics in oncology are difficult to tackle because there are a lot of clinical details that make it challenging to obtain and understand meaningful quality measures without getting in the way of the practice. However, she added that it’s important to balance multiple stakeholders’ needs in addressing quality measures as a means of helping patients find the best practices of care.
“The quality measures that are out there are allowing us to have the conversations with practices about how important quality is and how we can improve quality,” Dr Malin said. “But as a health plan, we really want to get to that next step of transparency and being able to share the quality scores of practices with our members so that they can use that information in helping to decide where to go to get care.”
When choosing between process measures or outcome measures, Dr Malin explained that the answer isn’t necessarily black and white. While it depends on the patient’s situation and the disease type, oncology specifically is a combination of both types of measures.
Complex cancer surgeries that demonstrate 30-day survival rates are paradigms that demonstrate meaningful outcome measures, but process measures allow health plans and providers to figure out what’s happening in real-time and what that quality currently looks like, she said. “For many other types of cancer though, the outcomes that are really meaningful happen 3, 4, or 5 years later. Commonly, we look at things like 5-year survival. Well that’s not very helpful in a setting of looking at quality of care, where you really want to know what’s happening now,” Dr Malin added.
Dr Malin suggested considering a blend of the 2 because outcome measures don’t necessarily demonstrate what needs to be improved in a timely manner, while process measures can quickly obtain that information.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More